{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"187"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Pre-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"175"},{"groupId":"OG002","value":"100"}],"units":"Participants"}],"title":"On-Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"83"}],"units":"Participants"}],"title":"Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"187"},{"groupId":"OG002","value":"100"}],"units":"Participants"}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"187"},{"groupId":"OG002","value":"100"}],"units":"Participants"}],"description":"Pre-treatment: From randomization to start of treatment. On-Treatment: From start of treatment to 30 days post-treatment or start of crossover treatment.\n\nExtension-treatment: From start of crossover treatment to 30 days post-crossover treatment.\n\nPost-treatment: From 31 days after last dose of treatment to the end of study.","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"},{"description":"Pemetrexed plus cisplatin or carboplatin (based on Investigator's choice) for 4 cycles (Induction) followed by pemetrexed as single agent (Maintenance)","id":"OG001","title":"Chemotherapy"},{"description":"Patients randomized to chemotherapy who crossed over to ceritinib at the extension-treatment period","id":"OG002","title":"Chemotherapy to Ceritinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization.\n\nFor the Chemotherapy/Ceritinib group, the analysis included patients randomized to the chemotherapy arm who crossed over and received at least one dose of ceritinib","reportingStatus":"POSTED","timeFrame":"Pre-treatment: up to 28 days; On-Treatment: up to approx. 120 months; Extension-treatment: up to approx. 108 months; Post-treatment: up to approx. 120 months","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}